North Central London
Joint Formulary
 
back
5 Infections

Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:

05-03-03-02 Chronic hepatitis C

Dasabuvir
Restricted

Provider notes

  • NMUH:
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • Check MHRA Drug Safety Updates
  • RFL:
    • For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Elbasvir + Grazoprevir
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Glecaprevir + Pibrentasvir
Formulary

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C

GP - Red View adult BNF  View SPC online  View childrens BNF
Ledipasvir + Sofosbuvir
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Ombitasvir + paritaprevir + ritonavir Viekirax®
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi nd Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Ribavirin
Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for hepatitis B (see NICE TA for eligibility criteria) and chronic hepatitis E viraemia in immunosuppressed individuals (JFC June 2016)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See links below
    • Ribavirin is listed on this formulary for treatment of chronic hepatitis C and for immunosuppressed individuals with chronic hepatitis E viraemia
    • Ribavirin should only be prescribed by Hepatologists
  • RFL:
    • Virology/Microbiology/ID approval only.
    • Hepatology use approved for the treatment of Hepatitis C in line with NICE guidance and Hepatitis E
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per JFC and NICE TA
    • Ribavirin should only be prescribed by Hepatologists
Link  NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA300: Hepatitis C - peginterferon alfa and ribavirin in children and young people
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Sofosbuvir
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA330: Sofosbuvir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Sofosbuvir + Velpatasvir
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Sofosbuvir + Velpatasvir + Voxilaprevir
Restricted

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF